POM-V Prescription Required

Equisolon 300 mg Oral Powder for Horses

Active ingredient: Prednisolone

Form

Powder

Species

Horses

Manufacturer

Le Vet B.V.

VMD MA No.

19994/5001

What it's used for

Streptococci (including S. uberis). Escherichia coli (including β-lactamase producing strains). AN: 01491/2024 & 01490/2024

Full indications, dosage and side effects ↓

View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Prednisolone

1

Ask your vet for a written prescription

They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
2

Fill it at a registered online retailer

The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Your prescription rights → VMD register of retailers →

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Equisolon 300 mg Oral Powder for Horses — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 27 Mar 2026.

Streptococci (including S. uberis).
Escherichia coli (including β-lactamase producing strains).
AN: 01491/2024 & 01490/2024

To ensure a correct dosage, body weight should be determined as accurately as
possible.
A single dose of 1 mg prednisolone/kg body weight per day corresponds to 100 mg
prednisolone in a 3 g sachet per 100 kg body weight (see dosing table below).
Treatment may be repeated at 24 hour intervals during 10 consecutive days.
The correct dose should be mixed into a small amount of food.
Food mixed with the veterinary medicinal product should be replaced if not
consumed within 24 hours.
Sachets of different pack size can be combined to achieve the correct dose, as per
the table below:
Number of sachetsBodyweight (kg)
of horse
100 mg prednisolone
(3 g sachet)
300 mg prednisolone
(9 g sachet)
600 mg prednisolone
(18 g sachet)
100-2002200-3001300-40011400-50021500-6001600-70011700-80021800-90011900-1000111

Do not use in cases of hypersensitivity to the active substance, to corticosteroids or
to any of the excipients.
Do not use in viral infections during the viraemic stage or in cases of systemic
mycotic infections.
Do not use in animals suffering from gastrointestinal ulcers.
Do not use in animals suffering from corneal ulcers.
Do not use during pregnancy.

Horses:
Very common
(>1 animal / 10 animals
treated):
Adrenal gland disorder
a
Hypocortisolaemia
a

Elevated triglyceride
b
Very rare
(<1 animal / 10,000 animals
treated, including isolated
reports):
Laminitis
c
Neurological signs (e.g. Ataxia, Head tilt,
Incoordination)
Restlessness
Recumbency, Anorexia
Elevated serum alkaline phosphatase (ALP)
d
Gastric ulceration
e
, Colic, Intestinal disorder
e
Excessive sweating
Urticaria
a
Result of effective doses suppressing the hypothalamo-pituitreal adrenal axis.
Following cessation of treatment, signs of adrenal insufficiency extending to
adrenocortical atrophy can arise and this may render the animal unable to deal
adequately with stressful situations.
b
This can be a part of possible iatrogenic hyperadrenocorticism (Cushings disease)
involving significant alteration of fat, carbohydrate, protein and mineral metabolism,
e.g. redistribution of body fat, increase in body weight, muscle weakness and wastage
and osteoporosis may result.
c
Horses should be monitored frequently during the treatment period.
d
Could be related to enlargement of the liver (hepatomegaly) with increased serum
hepatic enzymes.
e
Gastrointestinal ulceration may be exacerbated by steroids in animals given non-
steroidal anti-inflammatory drugs and in animals with spinal cord trauma (see section
3.3).
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian,
to either the marketing authorisation holder or its local representative or the national
competent authority via the national reporting system. See the package leaflet for
respective contact details.

Corticoid administration is to induce an improvement in clinical signs rather than a
cure. The treatment should be combined with environmental control.
Each case should be assessed individually by the veterinarian and an appropriate
treatment program determined. Treatment with prednisolone should only be initiated
when satisfactory alleviation of clinical symptoms have not been obtained or are
unlikely to be obtained by environmental control alone.
Treatment with prednisolone may not sufficiently restore respiratory function in all
cases, and in each individual case the use of veterinary medicinal products with
more rapid onset of action may need to be considered.

Special precautions for safe use in the target species:
Do not use in animals suffering from diabetes mellitus, renal insufficiency, cardiac
insufficiency, hyperadrenocorticism, or osteoporosis.
Use of corticosteroids in horses has been reported to induce laminitis (see section
3.6). Therefore horses should be monitored frequently during the treatment period.
Because of the pharmacological properties of prednisolone, use with caution when
the veterinary medicinal product is used in animals with a weakened immune
system.
Whilst single high doses of corticosteroids are generally well tolerated, they may
induce severe side-effects in long term use. Dosage in medium to long term use
should therefore generally be kept to the minimum necessary to control symptoms.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals:
People with known hypersensitivity to corticosteroids or any of the excipients should
avoid contact with the veterinary medicinal product.
The veterinary medicinal product should not be administered by pregnant women,
due to the risk of foetal malformation.
Personal protective equipment consisting of gloves and protective mask should be
worn when handling the veterinary medicinal product.
In order to prevent dust formation, do not shake the veterinary medicinal product.
Special precautions for the protection of the environment:
Not applicable.

The concomitant use of this veterinary medicinal product with non-steroidal anti-
inflammatory drugs may exacerbate gastrointestinal tract ulceration. Because
corticosteroids can reduce the immunoresponse to vaccination, prednisolone should
not be used in combination with vaccines or within two weeks after vaccination.
Administration of prednisolone may induce hypokalaemia and hence increase the
risk of toxicity from cardiac glycosides. The risk of hypokalaemia may be increased if
prednisolone is administered together with potassium depleting diuretics.

Opened sachets should not be stored.

Meat and offal: 10 days.
Not authorised for use in mares producing milk for human consumption.
4.

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.